Delivery Order 36F79721D0166-36C26124N0446
Award Date
2/16/24
Potential Completion Date
5/16/24
Potential Value
Not listed
Federal Agency
Veterans Integrated Service Network 21
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27703, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $113,440.80 delivery order to Biocryst Pharmaceuticals, Inc. under the firm fixed price Pharmaceuticals and Drugs Federal Supply Schedule contract. This order is for the delivery of BEROTRALSTAT HCL 150MG CAP,ORAL BULK to the place of performance in Durham, North Carolina by May 31, 2023. The contract was awarded on June 1, 2022 and has no set-aside designation. Biocryst...
This federal contract award is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 20 (VISN 20). The prime contractor is Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, which has a ceiling...
Biocryst Pharmaceuticals, Inc. was awarded a $56,670.76 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The contract calls for the delivery of berotralstat to Roseburg, Oregon with a period of performance concluding on January 19, 2024. No set-aside designation was applied to this award issued against GSA Schedule 61-IB for pharmaceutical...
This is a $382,300.88 firm fixed-price delivery order contract awarded by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing drugs for rare diseases. The contract is for the bulk order of ORLADEYO, a drug used to treat hereditary angioedema, to support veteran healthcare. The contract is not set aside and is part of Biocryst's Federal Supply Schedule (FSS)...
This federal contract award is for the delivery of BEROTRALSTAT HCL 150MG CAP (trade name ORLADEYO 150MG CAP) to the U.S. Department of Veterans Affairs (VA). The $379,348.93 contract was awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. This is a Firm Fixed Price delivery order placed under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an...
This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a Civilian agency, to Biocryst Pharmaceuticals Inc., a for-profit pharmaceutical company based in Durham, North Carolina. The contract, valued at $22,500,000.00, is for the delivery of drugs and biologicals, with a period of performance ending on November 2, 2011. The contract is a Firm Fixed Price Delivery Order and is not designated as a set-aside. Biocryst Pharmaceuticals Inc....
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that specializes in rare, autoimmune, and inflammatory disease treatments. The $74,667.32 firm fixed-price delivery order was placed against Horizon's existing Pharmaceuticals and Drugs (FSS-61-IB) Multiple Award Schedule contract with the General Services...
The U.S. Department of Veterans Affairs (VA) awarded a $370,099.80 Firm Fixed Price delivery order to UCB, Inc., a global biopharmaceutical company, under the VA's General Services Administration (GSA) Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. This delivery order is for the drug ZilbrysQ to treat patients within the VA healthcare system. UCB, Inc. holds multiple Blanket Purchase Agreements (BPAs) with the VA National Acquisition Center, including a $264,295.45 BPA for...
This is a Firm Fixed Price delivery order awarded by the Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, for the procurement of BREYANZI, a specialized chimeric antigen receptor (CAR) T cell therapy. The $335,042.65 contract is for the "EMERGENCY BREYANZI INFUSION" and an extension of the same, to be delivered to the VA's Veterans Integrated Service Network 8. This order falls under Bristol-Myers Squibb's $12,278,876,570.00...